For instance, the DNA methylation signature can be used to assign BCP-ALL cases to a specific subtype and to predict disease outcome, while loss-of-function mutations in methyltransferases (such as NSD2) or KATS (like CREBBP or EP300) may be used to predict prognosis and response to chemotherapy. This evidence concerns the gene NSD2 and acute lymphoblastic leukemia.